



HAL
open science

Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas.

Elodie Mutel, Aya Abdul-Wahed, Nirilanto Ramamonjisoa, Anne Stefanutti, Isabelle Houberdon, Sophie Cavassila, Frank Pilleul, Olivier Beuf, Amandine Gautier-Stein, Armelle Penhoat, et al.

► To cite this version:

Elodie Mutel, Aya Abdul-Wahed, Nirilanto Ramamonjisoa, Anne Stefanutti, Isabelle Houberdon, et al.. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas.. *Journal of Hepatology*, 2011, 54 (3), pp.529-37. 10.1016/j.jhep.2010.08.014 . hal-00575314

HAL Id: hal-00575314

<https://hal.science/hal-00575314v1>

Submitted on 15 Mar 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease
type 1a including development of multiple adenomas**

1
2
3
4
5
6 Elodie Mutel¹⁻³, Aya Abdul-Wahed¹⁻³, Nirilanto Ramamonjisoa N. ²⁻⁴, Anne Stefanutti¹⁻³,
7
8 Isabelle Houberton¹⁻³, Sophie Cavassila²⁻⁴, Frank Pilleul²⁻⁴, Olivier Beuf²⁻⁴, Amandine
9
10 Gautier-Stein¹⁻³, Armelle Penhoat¹⁻³, Gilles Mithieux¹⁻³ & Fabienne Rajas¹⁻³
11
12
13
14

15
16 ¹Institut National de la Santé et de la Recherche Médicale, U855, Lyon, F-69008, France
17

18 ²Université de Lyon, Lyon, F-69008 France
19

20 ³Université Lyon1, Villeurbanne, F-69622 France
21

22 ⁴Creatis-LRMN ; CNRS UMR 5220; Inserm U630; INSA-Lyon ; Villeurbanne, F-69622
23
24
25 France
26

27
28
29
30 **Address for correspondence:** Dr. Fabienne Rajas
31
32 Faculté de Médecine Laennec
33
34 7 rue Guillaume Paradin
35
36 69372 Lyon cedex 08 France
37
38 Tel: 33 478 77 10 28/Fax: 33 478 77 87 62
39
40 E-mail: fabienne.rajas@univ-lyon1.fr
41
42

43 **Running title:** Liver glycogen storage disease 1a mouse model
44

45 **Electronic word count:** 5450
46

47 **Number of figures and tables:** 6 Figures and 1 Table
48

49
50 **Abbreviations used:** Glucose-6 phosphatase (G6Pase), Catalytic subunit of G6Pase
51
52 (G6PC), Glycogen storage disease type 1a (GSD1a), wild type (wt), Non esterified fatty
53
54 acid (NEFA), Hepatocellular adenomas (HCA), magnetic resonance imagery (MRI)
55
56

57 **Conflict of interest:** The authors have declared that no conflict of interest exists.
58
59
60
61
62
63
64
65

ABSTRACT

Background & aims: Glycogen storage disease type 1a (GSD1a) is an inherited disease caused by a deficiency in the catalytic subunit of the glucose-6 phosphatase enzyme (G6Pase). GSD1a is characterized by hypoglycaemia, hyperlipidemia, lactic acidosis, with associated hepatic (including hepatocellular adenomas), renal, and intestinal disorders. A total *G6pc* (catalytic subunit of G6Pase) knock-out mouse model has been generated that mimics the human pathology. However, these mice rarely live longer than 3 months and long-term liver pathogenesis cannot be evaluated. Here, we report the long-term characterization of a liver-specific *G6pc* knock-out mouse model (*L-G6pc*^{-/-}). **Methods:** We generated *L-G6pc*^{-/-} mice using an inducible CRE-lox strategy and followed up the development of hepatic tumours using magnetic resonance imaging. **Results:** *L-G6pc*^{-/-} mice are viable and exhibit normoglycaemia in the fed state. They develop hyperlipidemia, lactic acidosis and uricemia during the first month after gene deletion. However, these plasmatic parameters improved after 6 months. *L-G6pc*^{-/-} mice develop hepatomegaly with glycogen accumulation and hepatic steatosis. Using a MRI approach, we could detect hepatic nodules with diameters of less than 1mm, from 9 months after induction of deficiency. Hepatic nodules (1mm) were detected in 30-40% of *L-G6pc*^{-/-} mice at 12 months. After 18 months, all *L-G6pc*^{-/-} mice developed multiple hepatocellular adenomas of 1 to 5 mm diameter. **Conclusion:** This is the first report of a viable animal model of the hepatic pathology of GSD1a, including the late development of hepatocellular adenomas.

Key words: glycogen storage disease, glucose-6 phosphatase, endogenous glucose production, hepatic steatosis, hepatic adenomas

Introduction

1
2 Glycogen storage disease type I (GSD1) is a metabolic disorder characterized by severe
3
4 hypoglycaemia associated with hepatic, renal and intestinal disorders [1]. This inborn
5
6 disease is due to a deficiency in glucose-6 phosphatase (G6Pase) activity. G6Pase is an
7
8 essential enzyme of endogenous glucose production. Patients affected with GSD1 are
9
10 therefore unable to maintain blood glucose concentration outside the time of meals and
11
12 suffer from severe hypoglycaemic episodes if they are not managed by continuous feeding
13
14 [2-4]. GSD type 1a and type 1b respectively correspond to inherited mutations in the
15
16 genes that encode the catalytic subunit (G6PC) and the transporter unit (G6PT) of the
17
18 G6Pase system [1, 2, 5, 6]. The *G6pc* gene is expressed in the liver, kidney, and intestine,
19
20 and these are the only organs that release glucose into the blood circulation [7-10].
21
22 G6Pase deficiency leads to accumulation of glucose-6 phosphate (G6P), glycogen, and
23
24 triglycerides in the liver and kidneys of patients. This results in marked hepatomegaly and
25
26 nephromegaly. In the liver, the long term complications of G6Pase deficiency include focal
27
28 nodular hyperplasia and more often hepatocellular adenomas (HCA) with risk of malignant
29
30 transformation [11, 12]. These tumours are often bleeding, multiple and non-encapsulated.
31
32 The current treatments to prevent hypoglycaemia are based on nocturnal nutrition [13].
33
34 When HCA or liver failure occur, the management strategies are resection of the tumour
35
36 and/or liver transplantation [14, 15].
37
38

39
40 To gain further insights into the long-term mechanisms of the disease and to evaluate
41
42 potential treatment strategies, an animal model with sufficient life expectancy is required.
43
44 Identification of the *G6pc* gene in 1993 has enabled a *G6pc*-knockout mouse model to be
45
46 developed [16, 17], as well as the evaluation of gene therapy approaches to correct *G6pc*
47
48 deficiency ([18, 19], see [20] for review). However, long-term complications cannot be
49
50 evaluated because even with continuous glucose therapy, the total *G6pc* knock-out mice
51
52 rarely live to be over 3 months of age [16]. To investigate the long-term biology and
53
54
55
56
57
58
59
60
61
62
63
64
65

pathogenesis of GSD-1a, we generated liver-specific *G6pc*^{-/-} mice by an inducible CRE
(CRE^{ERT2}) strategy. We give a detailed characterization of this novel GSD1a mouse model
over 18 months following inactivation of the *G6pc* gene in the liver.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

MATERIALS AND METHODS

Generation of B6.g6pc^{lox} mice

The targeting vector used for the homologous recombination strategy is shown in Figure 1A and contained a 4.5 kb 5' homologous *g6pc* arm, a 3 kb 3' homologous *g6pc* arm and a neomycin resistance (Neo^R) cassette. Two *loxP* sites flank *G6pc* exon 3 and two *Frt* sites flank Neo^R. We electroporated 129S2/SvPas mouse embryonic stem (ES) cells with the linearized construct. After selection, targeted clones were identified by PCR with external primers, with confirmation by Southern blotting with 5' and 3' external probes. Two positive ES clones were injected into C57BL/6J blastocysts. The male chimeras were mated with transgenic females expressing Flp recombinase to delete the Neo^R cassette. Then, the B6;g6pc^{lox/w} mice were backcrossed with the C57Bl/6J strain for 10 generations (Charles Rivers Laboratories).

Generation of liver-specific *G6pc*-null mice

The B6.g6pc^{lox/w} mice were crossed with transgenic mice expressing the inducible CRE^{ERT2} recombinase under the control of the serum albumin promoter to confer its liver-specific expression (B6. SA^{creERT2/w}) [21]. B6. SA^{creERT2/w} mice expressed, only in the liver, a recombinant Cre recombinase fused to a mutated ligand-binding domain of the estrogen receptor resulting in a tamoxifen-dependent Cre-recombinase [22, 23]. To induce the excision of *G6pc* exon 3, male adult (6 to 8 weeks old) B6.g6pc^{lox/lox}.SA^{creERT2/w} and B6.g6pc^{lox/w}.SA^{creERT2/w} mice were injected intraperitoneally once daily with 100 µl of tamoxifen (10 mg/ml, Sigma-Aldrich) on five consecutive days, to obtain L-g6pc^{-/-} and L-g6pc^{+/-} mice, respectively. Control C57Bl/6J mice were treated with similar tamoxifen injections. All mice were housed in the animal facility of Lyon 1 University (*Animaleries Lyon Est Conventiionnelle et SPF*) in controlled temperature (22°C) conditions, with a 12-hour light-12-hour dark cycle. Mice had free access to water and standard rodent chow

(Safe). Fasted mice were provided with continual free access to water. All procedures were performed in accordance with the principles and guidelines established by the European Convention for the Protection of Laboratory Animals. The regional animal care committee (CREEA, CNRS, Rhône-Alpes Auvergne, France) approved all experiments. Mouse genotypes were determined from genomic DNA by PCR, with specific primers (Table 1, see Figure 1). Genomic DNA was extracted from tissues in PCR Direct Lysis buffer (Euromedex).

Magnetic resonance imaging

As previously described [24, 25], we performed MRI scans on mice anesthetized by isoflurane inhalation. This was done using a horizontal Biospec-7T Bruker system (Bruker, Ettlingen, Germany) with a cylindrical volumetric coil of 32 mm internal diameter (Rapid Biomedical, Würzburg, Germany). The body temperature of the mice was maintained at 37°C by warm water circulation. A pressure sensor was placed on the abdomen to monitor the respiratory cycle and to synchronize image acquisition with respiratory motion using a Trigger Unit HR V2.0 (Rapid Biomedical, Würzburg, Germany). Scout scans were performed to identify regions of interest and the graphical prescriptions for the following scan. Then, T2-weighted contrast images were acquired and analyzed in the axial plane based on a fat suppressed (FS) rapid acquisition with relaxation enhanced (RARE) sequence with the following parameters: echo time (TE) 40.4 ms, field of view (FOV) 30 x 30 mm², matrix 256 x 192, 36 or 48 slices, slice thickness 0.5 mm, RARE factor =8. As previously described [24], the sequence was synchronized with respiration using balanced acquisitions over several respiratory periods with an effective repetition time (TR) of about 6 sec. Reading of MR images to detect adenomas was performed by a trained radiologist who had over fifteen years of experience.

Metabolic studies

1 Blood was withdrawn from the tail vein and collected into EDTA or sodium fluoride/oxalate
2
3 (anticoagulant). Plasma glucose, triglycerides, total cholesterol, uric acid and lactate
4
5 concentrations were determined with Biomérieux colorimetric kits. Glucose-6 phosphate
6
7 and glycogen determinations were carried out on frozen tissue homogenates as previously
8
9 described [26, 27].
10
11
12
13
14
15

Gene expression analysis

16
17
18 Mice were killed by cervical dislocation 6 h after food removal. The frozen tissues were
19
20 sampled, and G6Pase and PEPCK activities determined as previously described [10, 28-
21
22 30]. Immunoblotting was carried out using purified anti-rat G6PC (use at 1:1,500) or anti-
23
24 PEPCK (use at 1:5,000; Santa Cruz Biotechnology) antibodies [31]. Total RNAs were
25
26 isolated from tissues with TRIzol reagent (Invitrogen). Reverse transcription and real-time
27
28 PCR were performed as previously described [32], using sequence-specific primers (Table
29
30 1). The mouse ribosomal protein mL19 transcript (*Rpl19*) was used as a reference.
31
32
33
34
35
36
37

Histological analysis

38
39
40 Tissues were fixed with 10% formalin and embedded in paraffin. Cross-sections (5 μ m
41
42 thick) were cut and stained with hematoxylin and eosin (H&E), periodic Acid Schiff (PAS)
43
44 and picosirius red staining. The slides were examined on a Coolscope microscope (Nikon,
45
46 Tokyo, Japan).
47
48
49
50
51

Statistical analyses

52
53
54 Results are reported as means \pm SEM. The various groups were compared by Mann-
55
56 Whitney tests. Differences were considered statistically significant if $P < 0.05$.
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

RESULTS

Generation of a time-dependent and liver-specific deficiency of G6Pase in mice

We disrupted G6Pase activity in the liver, by time dependent (conditional) and tissue-specific invalidation of the *G6pc* gene, based on a CRE-lox strategy. As endogenous glucose production, especially from the liver, is critical during the neonatal period (because of the low content of glucose in milk) [33, 34], we have induced gene deletion in adult mice.

Male B6.g6pc^{lox/w}.SA^{creERT2/w} and B6.g6pc^{lox/lox}.SA^{creERT2/w} mice (see genotyping in Figure 1B) were therefore treated with tamoxifen at 7-8 weeks of age. This resulted in the specific excision of exon 3 from both *G6pc* alleles, in the liver (Figure 1C). The liver-specific deletion of exon 3 in *G6pc* was confirmed at the mRNA level by RT-PCR on mRNA from the liver, kidney, and intestine of L-*G6pc*^{-/-} and L-*G6pc*^{+/-} mice. Truncated *G6pc* mRNA was only amplified in the liver from L-*G6pc*^{-/-} and L-*G6pc*^{+/-} mice (Figure 1D). Hepatic G6Pase activity was undetectable after one month of gene deletion (0.31±0.13 U/g of protein in L-*G6pc*^{-/-} versus 68.0±2.1 U/g of protein in control mice) (Figure 2A). Liver G6Pase activity remained undetectable in L-*G6pc*^{-/-} mice (0.30±0.08 U/g of protein in L-g6pc^{-/-}) after 18 months, confirming the persistence of the *G6pc* inactivation. Western blot analyses confirmed the absence of the G6PC protein from the livers of L-*G6pc*^{-/-} mice (Figure 2A). In heterozygous mice (L-*G6pc*^{+/-}), G6Pase activity was only half of that in control mice (39.2±2.9U/g of protein in L-g6pc^{+/-}) and was correlated with the amount of G6PC protein detected on western blots (Figure 2A). Transcription of truncated *G6pc* mRNA appeared to be up regulated, with three times more *G6pc* mRNA in the liver of L-*G6pc*^{-/-} mice than in controls (Figure 2B). This implies that there is a compensatory increase in gene expression in response to the absence of G6PC protein. The expression of cytosolic phosphoenolpyruvate carboxykinase (PEPCK-c, *Pck1*) was unaltered (Figures 2C and 2D).

1 Expression of the genes encoding glucose-6-phosphate translocase (*G6PT*, *Slc37a4*) and
2 the transporter subunit of G6Pase remained unchanged (Figure 2E). Expression of the
3 ubiquitous (non gluconeogenic) glucose-6-phosphatase-related protein (G6PC3 or UGRP)
4 was also unaffected (Figure 2F).
5
6
7
8
9

10 **Metabolic effects of hepatic *G6pc* deficiency in mice**

11 The male and female L-*G6pc*^{-/-} mice showed similar survival rates to C57Bl/6J control (wt)
12 and L-*G6pc*^{+/-} heterozygous mice (data not shown). However, in contrast to total *G6pc*^{-/-}
13 mice, which are reported to have growth retardation [16], the loss of G6Pase specifically in
14 the liver during adulthood had only marginal effect, if any, on weight gain (Figure 3A).
15 Therefore, L-*G6pc*^{-/-} mice are fully viable and do not require glucose therapy to survive
16 [16]. After some hours of fasting, the blood glucose concentration in L-*G6pc*^{-/-} mice could
17 be lowered to about 3 mM (data not shown). This is consistent with the crucial role of
18 hepatic glycogenolysis in endogenous glucose production during the early post-absorptive
19 state. However, in the fed state, mean blood glucose concentration in L-*G6pc*^{-/-} mice was
20 similar to L-*G6pc*^{+/-} and control mice (Figure 3B). The blood glucose concentrations of L-
21 *G6pc*^{+/-} mice were similar to those of control mice (around 150 mg/dL), even after 6h of
22 fasting (data not shown). This is consistent with the absence of blood glucose problems
23 and any pathological phenotype in heterozygous human patients [3].
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Biochemical analyses revealed highly disturbed plasma parameters just after deletion of
46 *G6pc* in the liver. After ten days, L-*G6pc*^{-/-} mice had plasma triglyceride and uric acid
47 concentrations that were three times as high as those in control mice as well as plasma
48 cholesterol concentrations that were twice as high (Figures 3C-E). L-*G6pc*^{-/-} mice also had
49 a plasma lactic acid concentration that had increased by 50% compared with control mice
50 (Figure 3F). These concentrations remained high one month after gene deletion, but they
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

then normalized with time; all metabolic plasma parameters except for cholesterol were normalized after 18 months (Figures 3C-F).

LG6pc^{-/-} mice develop hepatomegaly and steatosis

As in GSD-1a patients and total *G6pc* knock-out mice, loss of hepatic G6PC led to accumulation of hepatic glucose-6 phosphate (G6P), glycogen, and triglycerides, which resulted in hepatomegaly and steatosis (Figure 4). The livers of L-*G6pc*^{-/-} mice were enlarged and pale (Figure 4A) and accounted for about 8% of total body mass, *versus* only 4% in control mice (Figure 4C). The deposition of glycogen increased between 10 days and one month after deletion, to reach about 50 mg of glycogen/g in L-*G6pc*^{-/-} liver at 18 months (Figures 4E). Accumulation of triglycerides in L-*G6pc*^{-/-} livers also increased with time (Figure 4F). Histological observations of L-*G6pc*^{-/-} livers confirmed marked steatosis, with large hepatocytes containing large lipid vacuoles, mainly in the periportal area (Figure 5F-G). As a result, the portal space was small and distorted (Figure 5G). Marked glycogen accumulation was also observed by periodic acid-Schiff staining (Figure 5H). Picrosirius red staining of the L-*G6pc*^{-/-} livers did not reveal any areas of fibrosis (Figure 5I). In contrast with total *G6pc* knock-out [16], the kidneys and intestine in L-*G6pc*^{-/-} mice did not accumulate any glycogen. After 18 months, the weight (0.16±0.01g for L-*G6pc*^{-/-} *versus* 0.15±0.1g for controls) and histological features of L-*G6pc*^{-/-} kidneys were also completely normal (Figure 5J).

Late appearance of hepatocellular adenomas in L-*G6pc*^{-/-} mice

Because of the short lifespan of total *G6pc*^{-/-} mice in the absence of glucose or gene therapy treatment, there was no possibility of detecting HCA. However, in the present study, using MRI, we were able to evaluate the development of nodules in the liver of L-*G6pc*^{-/-} mice. MRI was performed every three months, from 3 to 18 months after gene deletion. In less than 15% (3 out of 26) of L-G6PC^{-/-} livers, small lesions could be detected

1 as early as 9 months (data not shown). In about 30% (8 out of 26) of L-G6PC^{-/-} mice, small
2 nodules in the liver of about 1 mm diameter were first detected after one year (Figure 6A).
3 At 15-16 months, 40-50% of L-G6pc^{-/-} mice had liver nodules between 1 and 3 mm
4 diameter. At 18 months, all (n=17) L-G6pc^{-/-} mice had developed liver nodules between 1
5 and 10 mm diameter (Figures 6 B and C). There was at least one, and up to 5 large
6 nodules (>4-5 mm) in each liver at this time (Figure 6 E-F). Panels 6 A and B show the
7 development of one nodule on MRI from 12 months (6A) through to 18 months (6B)
8 following gene deletion. No obvious necrosis or significant haemorrhage was seen. The
9 nodules were well demarcated from the surrounding liver, without a fibrous capsule
10 (Figures 6G and 6H). More than 20 biopsies of GSD1a livers (n=17 mice) were analyzed
11 by immunohistochemistry (H&S staining). No portal spaces were seen within the nodules.
12 In most cases (80%), the hepatocytes within the nodule were large and swollen, with pale
13 cytoplasm (Figures 6 G and 6I). Areas of necrosis and inflammation were seen within the
14 nodules (Figure 6I). The tumour shown in Figure 6G proved to be an adenoma. In a few
15 cases (about 20%), the hepatocytes within the nodules were small, suggesting the
16 development of a “precarcinoma” lesion (Figures 6H and 6J). Areas of necrosis and
17 numerous foci of inflammation were also present within these nodules (data not shown). In
18 no case, pericellular fibrosis was observed around hepatic nodules. Moreover, no atypia
19 was noted in any of the nodules. No mice developed hepatocellular carcinoma in the
20 course of this study.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

DISCUSSION

The maintenance of blood glucose levels within a narrow range (about 1g/L) is a critical physiological function. Outside of the time of meals and during fasting, endogenous glucose production is wholly responsible for maintaining plasma glucose levels. Glucose can be produced only in the liver, kidney, and intestine, because these are the only organs known to express G6Pase, the key enzyme for endogenous glucose production (for review see [9]). Among these organs, the liver has a special role because it is able to rapidly mobilize glucose stored under the form of glycogen. Although the liver is the main glucose-producing organ under post-absorptive conditions, we hypothesized that the inactivation of *G6pc* in the liver only would not be lethal, because of compensatory glucose production by the kidneys and intestine. This type of compensation has already been reported during the anhepatic phase of liver transplantation in humans [35], and has been suggested in mice with inactivation of *Pck1* in the liver [36]. In line with our hypothesis, L-*G6pc*^{-/-} mice are normoglycemic in the fed state. This strongly suggests that glucose release by the kidney and intestine is sufficient to exquisitely regulate blood glucose concentration in L-*G6pc*^{-/-} mice when unrestrained food is available. Furthermore, L-*G6pc*^{-/-} mice had a normal survival rate, which allowed us, for the first time, to evaluate the development of GSD1a pathology in the livers of the mice, up to 18 months of age.

As expected, the liver of L-*G6pc*^{-/-} mice is rapidly enlarged, due to the accumulation of glucose-6 phosphate, glycogen, and triglycerides. In parallel, there is a rapid increase in plasma triglycerides, cholesterol, lactic, and uric acids, as also observed in human GSD1a patients and in total *G6pc* knock-out mice [3, 4]. Together with the absence of kidney and gut deficiency and phenotype in L-*G6pc*^{-/-} mice, this strongly suggests that the liver deficiency may be fully responsible for the deregulation of plasma parameters in GSD1a. Whereas some liver parameters tended to worsen with time (e.g. liver TG content), others

(blood parameters) progressively decreased towards control values (e.g. uricemia and lactatemia). This suggests that there are some compensatory mechanisms taking place over time to correct the primary defaults initiated by the liver deficiency. Interestingly, a comparable improvement of blood biochemical profile was also observed after some months in the total *G6pc* knock-out mice surviving thanks to pre-weaning management with glucose injection and post-weaning management with Nutragel and glucose added to the drinking water [37]. However, as in *LG6pc^{-/-}* mice, liver histology and glycogen accumulation did not improve with aging [37]. Therefore, it is probable that a satisfying control of blood glucose could explain this amelioration (dependent either on exogenous supply or on compensation by extrahepatic endogenous sources). This is also in line with the observation that GSD1a pathology is better tolerated with patient aging, and that some of the metabolic plasma parameters have been reported to be at least partially corrected with time [3].

To detect the putative appearance of hepatic adenomas as soon as possible while preserving the living animal, we used MRI, a powerful imaging technique, which allowed us to identify hepatic nodules about 1 mm in diameter. The first nodules were detected at 9 months of age, and after 18 months all livers in *L-G6pc^{-/-}* mice showed at least one large-sized lesion. As in human GSD1a, the adenomas were multiple, non-encapsulated, and in about 20% of cases, showed features of pre-carcinomas. It should be noted that adenomas were first detected at 9 months, a time when several plasma parameters had been normalized. However, this late detection cannot exclude that the development of adenomas may have started much earlier but they were not large enough to be detected by MRI. However, it is important to note that the development of adenoma appeared rather lately, whilst liver steatosis tended to worsen (see Figure 4). In the same time, several plasma parameters were markedly corrected, suggesting that the development of HCA was dependent on the alteration of liver metabolism and not on the deregulation of the

plasma parameters. Moreover, intrahepatic metabolic disturbances induced by G6Pase deficiency had the capacity to initiate adenoma formation in all of the livers studied. Furthermore, even if hepatocellular carcinoma was not observed, a substantial proportion of the adenomas could be prone to develop into carcinomas.

In conclusion, we report the characterization of a novel animal model of GSD1a, which is exclusively targeted to the liver. We demonstrate that L-*G6Ppc*^{-/-} mice have all the hepatic symptoms of the human pathology, including hepatomegaly, steatosis, glycogen overload. L-*G6pc*^{-/-} mice also have the expected dysregulations of plasma metabolites related to liver function such as triglycerides, cholesterol, lactic and uric acids. Our animal GSD1a model is perfectly viable without treatment and is normoglycaemic when food is available. Because of this, for the first time we are able to report that the development of adenomas is bound to happen with time in GSD1a livers. In addition, a significant proportion of these adenomas exhibit the features of pre-carcinomas. Because of its viability, this new animal model will be extremely useful for a better understanding of the pathological mechanisms of GSD1a. It will also be of value in assessing the effects of food quality on delaying the deleterious consequences of the disease (e.g. adenomas). Our model should be able to help refine the different gene therapy approaches aimed at correcting G6Pase expression in the liver. Finally, in the near future, the CRE-lox approach that was used to generate the liver-deficient model, will allow us to assess the consequences of kidney or intestine pathology. This will be based on the use of a CRE recombinase expressed under the control of adapted gut or kidney gene promoters to specifically target the deficiency to either organ.

ACKNOWLEDGMENTS

1
2 We would like to thank the Mouse Clinical Institute (Strasbourg, France) for invaluable help
3
4 in generating the B6.g6pc^{lox} mice. This work received financial support from the
5
6 “Association Française contre les Myopathies” (Paris, France) and the “GIS-Institut des
7
8 Maladies Rares” (Paris, France). We also thank Prof. Pierre Chambon and Dr. Daniel
9
10 Metzger (Mouse Clinical Institute, Strasbourg, France) for generously providing B6.
11
12 SA^{CreERT2} transgenic mice, Nicolas Gadot and Prof. Jean-Yves Scoazec (ANIPATH,
13
14 Faculty of Medicine Laennec, Lyons, France) for carrying out the histology study, Angèle
15
16 Chamousset and Jean-Michel Vicat for animal care (ALECS, Faculty of Medicine
17
18 Laennec, IFR62 Lyon-Est, Lyons), Jean-Baptiste Langlois for MRI acquisitions (Animage
19
20 Platform, Cermep, Lyons) and the members of the CECIL Platform (Faculty of Medicine
21
22 Laennec, IFR62 Lyon-Est, Lyons). This work was supported by research grants from the
23
24 “Agence Nationale de la Recherche” (ANR-07-MRAR-011-01) and the “Association
25
26 Francophone des Glycogénoses”.

REFERENCES

- 1 [1] Chou JY, Mansfield BC. Mutations in the glucose-6-phosphatase-alpha (G6PC)
2 gene that cause type Ia glycogen storage disease. *Hum Mutat* 2008;29:921-930.
3
4
5 [2] Chou JY, Matern D, Mansfield BC, Chen YT. Type I glycogen storage diseases:
6 disorders of the glucose-6-phosphatase complex. *Curr Mol Med* 2002;2:121-143.
7
8
9 [3] Moses SW. Historical highlights and unsolved problems in glycogen storage
10 disease type 1. *Eur J Pediatr* 2002;161 Suppl 1:S2-9.
11
12
13 [4] Ozen H. Glycogen storage diseases: new perspectives. *World J Gastroenterol*
14 2007;13:2541-2553.
15
16 [5] Bruni N, Rajas F, Montano S, Chevalier-Porst F, Maire I, Mithieux G. Enzymatic
17 characterization of four new mutations in the glucose-6 phosphatase (G6PC) gene which
18 cause glycogen storage disease type 1a. *Ann Hum Genet* 1999;63:141-146.
19
20 [6] Chevalier-Porst F, Bozon D, Bonardot AM, Bruni N, Mithieux G, Mathieu M, Maire I.
21 Mutation analysis in 24 French patients with glycogen storage disease type 1a. *J Med*
22 *Genet* 1996;33:358-360.
23
24
25 [7] Croset M, Rajas F, Zitoun C, Hurot JM, Montano S, Mithieux G. Rat small intestine
26 is an insulin-sensitive gluconeogenic organ. *Diabetes* 2001;50:740-746.
27
28 [8] Mithieux G, Bady I, Gautier A, Croset M, Rajas F, Zitoun C. Induction of control
29 genes in intestinal gluconeogenesis is sequential during fasting and maximal in diabetes.
30 *Am J Physiol Endocrinol Metab* 2004;286:E370-375.
31
32
33 [9] Mithieux G, Rajas F, Gautier-Stein A. A novel role for glucose 6-phosphatase in the
34 small intestine in the control of glucose homeostasis. *J Biol Chem* 2004;279:44231-44234.
35
36
37 [10] Rajas F, Bruni N, Montano S, Zitoun C, Mithieux G. The glucose-6 phosphatase
38 gene is expressed in human and rat small intestine: regulation of expression in fasted and
39 diabetic rats. *Gastroenterology* 1999;117:132-139.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [11] Cassiman D, Libbrecht L, Verslype C, Meersseman W, Troisi R, Zucman-Rossi J, Van Vlierberghe H. An adult male patient with multiple adenomas and a hepatocellular carcinoma: Mild Glycogen Storage Disease type Ia. *J Hepatol* 2010;53:213-217.
- [12] Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, Boney A, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. *J Inherit Metab Dis* 2005;28:153-162.
- [13] Heller S, Worona L, Consuelo A. Nutritional therapy for glycogen storage diseases. *J Pediatr Gastroenterol Nutr* 2008;47 Suppl 1:S15-21.
- [14] Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. *J Pediatr Gastroenterol Nutr* 1997;24:276-279.
- [15] Matern D, Starzl TE, Arnaout W, Barnard J, Bynon JS, Dhawan A, Emond J, et al. Liver transplantation for glycogen storage disease types I, III, and IV. *Eur J Pediatr* 1999;158 Suppl 2:S43-48.
- [16] Lei KJ, Chen H, Pan CJ, Ward JM, Mosinger B, Jr., Lee EJ, Westphal H, et al. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse. *Nat Genet* 1996;13:203-209.
- [17] Shelly LL, Lei KJ, Pan CJ, Sakata SF, Ruppert S, Schutz G, Chou JY. Isolation of the gene for murine glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1A. *J Biol Chem* 1993;268:21482-21485.
- [18] Ghosh A, Allamarvdasht M, Pan CJ, Sun MS, Mansfield BC, Byrne BJ, Chou JY. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. *Gene Ther* 2006;13:321-329.
- [19] Yiu WH, Lee YM, Peng WT, Pan CJ, Mead PA, Mansfield BC, Chou JY. Complete Normalization of Hepatic G6PC Deficiency in Murine Glycogen Storage Disease Type Ia Using Gene Therapy. *Mol Ther* 2010; 18:1076-1084

- 1 [20] Chou JY, Mansfield BC. Gene therapy for type I glycogen storage diseases. *Curr*
2 *Gene Ther* 2007;7:79-88.
- 3 [21] Schuler M, Dierich A, Chambon P, Metzger D. Efficient temporally controlled
4 targeted somatic mutagenesis in hepatocytes of the mouse. *Genesis* 2004;39:167-172.
5
6 [22] Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P. Ligand-activated
7 site-specific recombination in mice. *Proc Natl Acad Sci U S A* 1996;93:10887-10890.
8
9 [23] Nagy A. Cre recombinase: the universal reagent for genome tailoring. *Genesis*
10 2000;26:99-109.
11
12 [24] Baboi L, Pilleul F, Milot L, Lartizien C, Poncet G, Roche C, Scoazec JY, et al.
13 Magnetic resonance imaging follow-up of liver growth of neuroendocrine tumors in an
14 experimental mouse model. *Magn Reson Imaging* 2010;28:264-272.
15
16 [25] Beuf O, Lartizien C, Milot L, Baboi L, Roche C, Langlois JB, Scoazec JY, et al.
17 Multimodal imaging for the detection and characterization of liver lesions in a mouse model
18 of neuroendocrine tumor. *Gastroenterol Clin Biol* 2008;32:32-40.
19
20 [26] Guignot L, Mithieux G. Mechanisms by which insulin, associated or not with
21 glucose, may inhibit hepatic glucose production in the rat. *Am J Physiol* 1999;277:E984-
22 989.
23
24 [27] Mithieux G, Guignot L, Bordet JC, Wiernsperger N. Intrahepatic mechanisms
25 underlying the effect of metformin in decreasing basal glucose production in rats fed a
26 high-fat diet. *Diabetes* 2002;51:139-143.
27
28 [28] Daniele N, Rajas F, Payrastra B, Mauco G, Zitoun C, Mithieux G.
29 Phosphatidylinositol 3-kinase translocates onto liver endoplasmic reticulum and may
30 account for the inhibition of glucose-6-phosphatase during refeeding. *J Biol Chem*
31 1999;274:3597-3601.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [29] Mithieux G, Daniele N, Payrastre B, Zitoun C. Liver microsomal glucose-6-phosphatase is competitively inhibited by the lipid products of phosphatidylinositol 3-kinase. *J Biol Chem* 1998;273:17-19.
- [30] Rajas F, Croset M, Zitoun C, Montano S, Mithieux G. Induction of PEPCK gene expression in insulinopenia in rat small intestine. *Diabetes* 2000;49:1165-1168.
- [31] Rajas F, Jourdan-Pineau H, Stefanutti A, Mrad EA, Iynedjian PB, Mithieux G. Immunocytochemical localization of glucose 6-phosphatase and cytosolic phosphoenolpyruvate carboxykinase in gluconeogenic tissues reveals unsuspected metabolic zonation. *Histochem Cell Biol* 2007;127:555-565.
- [32] Pillot B, Soty M, Gautier-Stein A, Zitoun C, Mithieux G. Protein feeding promotes redistribution of endogenous glucose production to the kidney and potentiates its suppression by insulin. *Endocrinology* 2009;150:616-624.
- [33] Chatelain F, Pegorier JP, Minassian C, Bruni N, Tarpin S, Girard J, Mithieux G. Development and regulation of glucose-6-phosphatase gene expression in rat liver, intestine, and kidney: in vivo and in vitro studies in cultured fetal hepatocytes. *Diabetes* 1998;47:882-889.
- [34] Girard J, Ferre P, Pegorier JP, Duee PH. Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition. *Physiol Rev* 1992;72:507-562.
- [35] Battezzati A, Caumo A, Martino F, Sereni LP, Coppa J, Romito R, Ammatuna M, et al. Nonhepatic glucose production in humans. *Am J Physiol Endocrinol Metab* 2004;286:E129-135.
- [36] She P, Burgess SC, Shiota M, Flakoll P, Donahue EP, Malloy CR, Sherry AD, et al. Mechanisms by which liver-specific PEPCK knockout mice preserve euglycemia during starvation. *Diabetes* 2003;52:1649-1654.

[37] Salganik SV, Weinstein DA, Shupe TD, Salganik M, Pintilie DG, Petersen BE. A detailed characterization of the adult mouse model of glycogen storage disease Ia. *Lab Invest* 2009;89:1032-1042.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 **FIGURE LEGENDS**
4
5
6
7

8 **Figure 1. Targeting strategy used to generate liver-specific *g6pc* null mice (L-*g6pc*^{-/-}).**

9
10
11 **(A)** Scheme of the wild-type *G6pc* allele (*G6pc*^w), located on chromosome 11, and the
12 targeting vector. Black rectangles represent exons and the 5' and 3' untranslated
13 sequences are indicated by white rectangles. In the targeting vector map, LoxP sequences
14 are represented as triangles and flags indicate *frt* sequences. Neo^R: neomycin resistance
15 gene cassette. Bold line segments: arms of homology. After homologous recombination
16 between the *G6pc*^w locus and the targeting vector in ES cells, Neo^R was removed to obtain
17 the *G6pc*^{lox} allele through FLP recombination. Exon 3 of *G6pc* was specifically excised by
18 CRE recombination (*G6pc*^{del}). Specific primers (Table 1) for genotyping were identified (p1,
19 p2 and p3). **(B)** PCR genotype analysis on the basis of tail DNA, using the p2 and p3
20 primers, which yielded products of 385 and 486 bp for the wild-type and floxed *G6pc*
21 alleles, respectively. Specific primers were used to amplify a 320 bp *Cre* fragment. The
22 expected sizes are shown on the left of the panel. **(C)** PCR genotype analysis on the basis
23 of tail and liver DNA, using p1 and p3 primers. Fragments of 1189, 1029 and 595 bp
24 correspond to the *G6pc*^{lox}, *G6pc*^w and *G6pc*^{del} alleles, respectively. **(D)** Liver-specific
25 excision of *G6pc* exon 3. RT-PCR analysis on liver, kidney or intestine mRNA, from L-*g6pc*⁻
26 ^{-/-}, L-*g6pc*^{+/-} and L-*g6pc*^{+/+} (C57Bl/6J) mice, using *G6pc* exon 2 and exon 5 primers. A 761
27 bp DNA fragment is obtained from the wt allele and the deletion of exon 3 yields a 655 bp
28 DNA fragment. Comparable data were obtained at 10 days or 18 months after tamoxifen
29 treatment.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56
57 **Figure 2. Glucose-6-phosphatase is absent in the liver of liver-specific *G6pc*-null**
58 **mice (L-*G6pc*^{-/-}).** **(A and C)** G6Pase and PEPCK-c activities were assayed in the liver of
59
60
61
62
63
64
65

1 homozygous L-*G6pc*^{-/-} (black bar), heterozygous L-*G6pc*^{+/-} (grey bar) and wt (white bar)
2 mice. Top of panels, western-blot analyses of liver tissues for G6PC and PEPCK-c
3 proteins. **(B, D, E and F)** *G6pc*, *Pck1*, *G6pt (Slc37a4)* and *G6pc3* mRNA levels were
4 determined by RT-qPCR in the livers of L-*G6pc*^{-/-} (black bar), L-*G6pc*^{+/-} (grey bar) and wt
5 (white bar) mice. The results are expressed as a ratio relative to *Rpl19* expression. Data
6 were obtained five weeks after tamoxifen injections from mice fasting for 6 h and are
7 expressed as means ± SEM (n=6 mice per group). Values which are significantly different
8 from wt (P<0.05*, P<0.01**) are indicated.
9
10
11
12
13
14
15
16
17
18
19
20

Figure 3. Body weight and plasmatic parameters of L-*G6pc*^{-/-} mice. **(A)** Growth rates
21 of L-*G6pc*^{-/-} (black symbols) and wt (white symbols) male and female mice. Body weight
22 was followed once a month after gene deletion. Blood glucose **(B)**, triglycerides **(C)**, total
23 cholesterol **(D)**, uric acid **(E)** and lactic acid **(F)** were analysed at 10 days, 1 month, 6
24 months and 18 months after gene deletion in L-*G6pc*^{-/-} (black bars) and control L-*G6pc*^{+/+}
25 (white bars) mice upon 6 h of fasting, except for glucose, which was determined in the fed
26 state. The results are expressed as mean ± SEM(n=6 to 8 per group). Values significantly
27 different from wt (P<0.05* and P<0.01**) are indicated.
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Figure 4. Liver-specific *G6pc* null mice develop liver hepatomegaly and steatosis.
42 **(A)** Livers of L-*G6pc*^{-/-} and wt mice. **(B)** Liver weight, **(C)** Liver weight compared to the
43 body weight, **(D)** Liver glucose-6 phosphate content, **(E)** Liver glycogen content **(F)** Liver
44 triglyceride content of L-*G6pc*^{-/-} (black bar) and wt (white bar) mice. Data were obtained 10
45 days, 1 month and 18 months after tamoxifen injections, from mice fasted for 6 h and are
46 expressed as means ± SEM (n=6 mice per group). Values which significantly different from
47 wt (P<0.05*, P<0.01**) are indicated.
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 5. Histology and glycogen storage analyses of the liver and the kidneys of
61
62
63
64
65

1 **L-G6pc^{-/-} and control mice, one month after tamoxifen treatment.** H&E stained
2 sections from control liver **(A-B)** and kidneys **(E)** and from L-G6pc^{-/-} livers **(F-G)** and
3 kidneys **(J)**. PAS-stained liver from control **(C)** and from L-G6pc^{-/-} **(H)** mice. Picrosirius red
4 staining of control **(D)** and from L-G6pc^{-/-} **(I)** mice.
5
6
7
8
9


10 **Figure 6. Development of liver nodules in L-G6pc^{-/-} mice after one year of gene**
11 **deletion.** T2-weighted axial MR images showing the evolution of liver lesions at 12 months
12 **(A)** and 18 months **(B-C)** after G6pc deletion. Liver resection after 18 months of tamoxifen
13 treatment in control mice **(D)** or in L-G6pc^{-/-} mice **(E-F)** with multiple tumour nodules.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Table 1

Oligodeoxyribonucleotide primer sequences for PCR (top) and qPCR (bottom). S =
sense and AS= antisense sequences.


Name	Sequence
p1S	5'-AGGGAGTTGACCAGAGGAACTTTGG-3'
p2S	5'-GCTCATTCTCACACCTACAGTTGG-3'
p3AS	5'-TGTTCCCTAACTACTGAGCCATTGCTCC-3'
CreS	5'- TTCCCGCAGAACCTGAAGATGTTTCG-3'
CreAS	5'-GGGTGTTATAAGCAATCCCCAGAAATGC-3'
Exon 2 mG6pc S	5'-TCCCTGTCACCTGTGAG-3'
Exon 5 mG6pc AS	5'-CACAAGAAGTCTTTGTAA-3'
Exon1 mG6pcS	5'-TTACCAAGACTCCCAGGACTG-3'
Exon2 mG6pcAS	5'-GAGCTGTTGCTGTAGTAGTCG-3'
mL19S	5'-AGAAGATTGACCGCCATAT-3'
mL19AS	5'-TTCGTGCTTCCTTGGTCTTAGA-3'
G6pc3S	5'-GCACATTTCCCTCACCAAGT-3'
G6pc3AS	5'-GGTTGATGGACCAGGAAAGA-3'
G6ptS	5'-TGGTTGGTCTGGTCAACGTA-3'
G6ptAS	5'-TGCCAAGATAGGTCCCAAAC-3'
Pck1S	5'-AGCCTTTGGTCAACAACACTGG-3'
Pck1AS	5'-TGCCTTCGGGGTTAGTTATG-3'

Figure 1




Mutel et al., Figure 1

Figure 2



Mutel et al., Figure 2


Figure 3




Mutel et al., Figure 3

Figure 4


A




B




C



D



E



F






Figure 5



Mutel et al., Figure 5

Figure 6



Mutel et al., Figure 6